
Joanne B Weidhaas MD PHD, MSM
Professor, David Geffen School of Medicine at UCLA
Join to View Full Profile
200 Medical Plaza, Suite B265Los Angeles, CA 90095
Phone+1 310-825-9775
Fax+1 310-825-9775
Dr. Weidhaas is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- Stanford Graduate School of BusinessMS, Management, 2012 - 2013
- Memorial Sloan Kettering Cancer CenterResidency, Radiation Oncology, 2000 - 2004
- Steward Carney HospitalInternship, Internal Medicine, 1999 - 2000
- Tufts Sackler SchoolPhD, Molecular Biology and Microbiology, 1991 - 1999
- Tufts University School of MedicineClass of 1999
- Yale UniversityBS, Biology, 1986 - 1990
Certifications & Licensure
- CA State Medical License 2015 - 2027
- CT State Medical License 2004 - 2017
- NY State Medical License 2000 - 2006
- American Board of Radiology Radiation Oncology
Awards, Honors, & Recognition
- Yale Cancer Center Award, “Most Influential Paper in the Field" 2009
- Michael Fry Research Award 2009
- Recognition of Clinical Excellence Award Yale School of Medicine, 2006
- Join now to see all
Clinical Trials
- Mammosite Breast Brachytherapy Optimization in the Treatment of Breast Carcinoma Start of enrollment: 2006 May 01
- 4D Image-Guided Partial Breast Radiation in Stage 0 and l Breast Cancer Start of enrollment: 2012 Jan 10
- Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment
Roles: Contact
- Join now to see all
Publications & Presentations
PubMed
- The interplay between acute and late toxicity among patients receiving prostate radiotherapy: an individual patient data meta-analysis of six randomised trials.John Nikitas, Parsa Jamshidian, Alison C Tree, Emma Hall, David Dearnaley
The Lancet. Oncology. 2025-03-01 - 1 citationsPrediction of Radiation Treatment Response for Locally Advanced Rectal Cancer via a Longitudinal Trend Analysis Framework on Cone-Beam CT.Zirong Li, Ann C Raldow, Joanne B Weidhaas, Qichao Zhou, X Sharon Qi
Cancers. 2023-10-25 - The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC.Joanne B Weidhaas, Chen Hu, Ritsuko Komaki, Gregory A Masters, George R Blumenschein
Cancer Research Communications. 2023-10-11
Journal Articles
- A let-7 microRNA-Binding Site Polymorphism in KRAS Predicts Improved Outcome in Patients with Metastatic Colorectal Cancer Treated with Salvage Cetuximab/Panitumumab M...Saridaki Z, Weidhaas JB, Lenz HJ, Laurent-Puig P, Jacobs B, De Schutter J, De Roock W, Salzman DW, Zhang W, Yang D, Pilati C, Bouche O, Piessevaux H, Tejpar S, Clin Cancer Res, 9/1/2014
- A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinomaChung CH, Lee JW, Slebos RJ, Howard JD, Perez J, Kang H, Fertig EJ, Considine M, Gilbert J, Murphy BA, Nallur S, Paranjape T, Jordan RC, Garcia J, Burtness B, Forastie..., Ann Oncol, 7/1/2014
- Radiation therapy oncology group gynecologic oncology working group: comprehensive resultsGaffney DK, Jhingran A, Portelance L, Viswanathan A, Schefter T, Weidhaas J, Small W Jr, Int J Gynecol Cancer, 6/1/2014
- Join now to see all
Lectures
- The KRAS-variant in Head and Neck Cancer as a Predictive Biomarker, results of RTOG 05226/1/2014
- MicroRNAs in cancer risk, biology and treatment4/1/2014
- Yale Cancer Center Evening Oncology Series: Breast CancerYale CME, New Haven, Connecticut - 1/17/2012
- Join now to see all
Press Mentions
- MiraDx Announces New Study Published in Clinical Cancer Research Validating PROSTOX™ Ultra Diagnostic Test for Predicting Radiation-Induced Late Toxicity in Prostate CancerApril 7th, 2025
- New Test Identifies Prostate Cancer Patients at Risk for Long-Term Radiation Therapy Side EffectsApril 7th, 2025
- Test Predicts Which Patients with Prostate Cancer Most Likely to Develop Long-Term Side Effects from Radiation TherapyApril 7th, 2025
- Join now to see all
Grant Support
- Germ-line miRNA binding site variants as biomarkers of toxicity and response to checkpoint inhibitionUNIVERSITY OF CALIFORNIA LOS ANGELES2019–2025
- Let-7 Micrornas In Lung Cancer: Altering Growth And RadioresistanceNational Cancer Institute2009–2012
- Defining The Genetic Basis Of The Radioresponse Using A C. Elegans Tissue ModelNational Cancer Institute2007–2011
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: